President and Chief Executive Officer
Mr. Wheeler joined Momenta as CEO in September of 2006. He led the company through the launch of its first product, generic Lovenox. He has overseen the company’s growth into the diversified business it is today. In 2011 he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, The Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Previously he was President of Chiron BioPharmaceuticals. During his five year tenure Chiron’s pharmaceutical division more than doubled its global sales. He was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector. He began his career at Merck’s MSDRL research unit. He is Chairman of the GPhA’s Board of Directors and is also Chairman of the Board of Avanir Pharmaceuticals.
Senior Vice President, Human Resources
Ms. Beltramello joined Momenta in October of 2007. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.
Senior Vice President, Pharmaceutical Sciences
Vice President Program and Project Management
Mr. Fier joined Momenta in October of 2002. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA in Heath Care Management from Boston University.
President, Biosimilars Business and Senior Vice President
Dr. Franken joined Momenta in December of 2013. He was previously Senior Vice President and Chief Business Officer of Radius Health where he was responsible for the company's commercial, business development, and strategy functions. Prior to that, he served as Vice President and General Manager, Solid Organ Transplantation, at Genzyme Corporation, now a Sanofi Company, and also held progressively senior positions in corporate development portfolio and general management from 2000 until November 2011. Dr. Franken received his M.D. from the University of Heidelberg, Germany and a Master in Health Policy and Management from Harvard University's School of Public Health.
Co-Founder, Chief Scientific Officer and Senior Vice President, Research
Dr. Kaundinya is one of Momenta's founders. Since inception, Dr. Kaundinya has played a key role in defining the business and scientific strategy and in building and leading the research organization. Prior to founding Momenta, Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-milliondollar NIH initiative to study the role of complex sugars in biology.
Vice President, Corporate Development and Strategy
Dr. Kwon joined Momenta in January of 2011. At Momenta, he is responsible for driving business and corporate development strategy aimed at achieving Momenta’s corporate objectives. These objectives include further developing our biosimilars and novel drug businesses through strategic transactions like those with Baxter Healthcare, Virdante Pharmaceuticals and others. He was previously Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. He has co-authored numerous peer-reviewed publications in the area of neurobiology.
General Counsel, Senior Vice President and Secretary
Mr. Leicher joined Momenta in July of 2008. He was previously Senior Vice President and General Counsel at Altus Pharmaceuticals Inc. and also served as General Counsel and in senior legal positions at Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc., and Wyeth. Mr. Leicher brings significant legal expertise in research and product development, product commercialization and launch, corporate finance and partnering transactions, intellectual property law and licensing, corporate governance and litigation. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow and was an attorney at Hale and Dorr and Butler and Binion.
Chief Medical Officer and Senior Vice President, Development
Dr. Roach joined Momenta in February of 2008. He is responsible for preclinical and clinical development and regulatory affairs. Previously he was the Senior Vice President of Medical Affairs at Sepracor. He has also held senior clinical research and/or medical affairs positions at Millennium Pharmaceuticals, LeukoSite, Medical and Technical Research Associates and Astra USA. Dr. Roach is Board Certified in Internal Medicine and Pulmonary Disease. He has been affiliated with the Pulmonary and Critical Care Medicine Division of Brigham and Women’s Hospital since 1993 and is an Assistant Clinical Professor of Medicine at Harvard Medical School. Dr. Roach is also a Fellow of the American College of Physicians and the American College of Chest Physicians.
Chief Financial Officer and Senior Vice President
Mr. Shea joined Momenta in October of 2003. During his tenure Momenta has raised over $380 million, including the company’s IPO in June 2004. He was previously Chief Operating Officer, Chief Financial Officer and Treasurer at Variagenics, Inc., a pharmacogenomics company, where he assisted in raising over $120 million, including their IPO in July 2000. While at Variagenics, Mr. Shea was responsible for Finance, Legal, Investor Relations, Human Resources and Operations. Prior to this, Mr. Shea was Vice President of Finance at Genetics Institute, Inc. (now Pfizer), and a Senior Manager at PricewaterhouseCoopers.
Last revised 11/17/2014